News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2012

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

PDF 76 KB   Not for distribution in the United States Berlin, Germany – The Executive Board of Epigenomics AG (ISIN: E000A1K0516) notifies that during the preparation of the annual financial statements pursuant to German GAAP (HGB) accounting, according to its best judgment a cumulative loss of more than half of the nominal share capital […]

Read more

Epigenomics AG Provides Update on Financing Plans

20.12.2012 | 121220_Press_Release_Epigenomics_Update_Financing_Plans Not for distribution in the United States Berlin, Germany, and Seattle, WA, U.S.A., December 20, 2012 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced the intention to launch a capital increase by way of a rights issue in January 2013. With the capital increase the […]

Read more

Epigenomics Provides Additional Data on the Outcome of its Head-to-Head Comparison Study of Epi proColon® to FIT

19.12.2012 | 121219_Press_release_Epigenomics_AG_FIT_data Berlin, Germany, and Seattle, WA, U.S.A., December 19, 2012 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today provided detailed results from a head-to-head comparative study between its blood-based colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT) for which it recently reported top-line […]

Read more

Epigenomics AG Reports Non-Inferiority of Blood-based Epi proColon® against Fecal Immunochemical Testing in Detection of Colorectal Cancer in a Head-to-Head Comparative Study

04.12.2012 | 121204_Press_release_Epigenomics_AG_Head-to-Head_Comparative_Study Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced top-line results from a head-to-head comparative study between its blood-based colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT) to demonstrate the non-inferiority of Epi proColon® in detection of CRC.

Read more

Ad hoc: Epigenomics AG Reports Non-Inferiority of Blood-based Epi proColon® against Fecal Immunochemical Testing in Detection of Colorectal Cancer in a Head-to-Head Comparative Study

PDF 85 KB   Berlin, Germany, December 04, 2012 – Epigenomics AG (ISIN: DE000A1K0516) announces top-line results from a head-to-head comparative study between its blood-based colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT) to demonstrate the non-inferiority of Epi proColon® in detection of CRC. In the reported trial, Epi proColon® detected […]

Read more

Epigenomics AG Announces Nine Months 2012 Financial Results

07.11.2012 | 121107_Press_release_Epigenomics_AG_9M_results Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced its financial results for the first nine months and third quarterending September 30, 2012.

Read more